Prevalence, treatment, and outcome of infection due to extended-spectrum β-lactamase-producing microorganisms [3]

Infection Control and Hospital Epidemiology

Volumn 27, Issue 3, 2006, Pages 326-327

  Apisarnthanarak, Anucha ^a   Mundy, Linda M ^b  

^a THAMMASAT UNIVERSITY   (Thailand)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; BACTERIUM ISOLATE; CLINICAL LABORATORY; DISEASE SEVERITY; ESCHERICHIA COLI; FEMALE; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; LETTER; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MORTALITY; NONHUMAN; PREVALENCE; RETROSPECTIVE STUDY; SURGICAL INFECTION; THAILAND; TREATMENT OUTCOME; URINARY TRACT INFECTION; WOUND INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CROSS INFECTION; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; MALE; MIDDLE AGED; PREVALENCE; THAILAND;

EID: 33645561404     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/503020     Document Type: Letter

References (7)

1. Kang CI, Kim SH, Kim DM, et al. Risk factors for and clinical outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004; 25:860-867.
2. NCCLS. Performance Standards for Antimicrobial Susceptibility Testing. 14th Informational supplement. Wayne, PA: NCCLS; 2004. NCCLS document M100-S14.
3. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions for nosocomial infections. Am J Infect Control 1992; 20:271-4.
4. Emery CL, Weymouth LA. Detection and clinical significance of extended-spectrum beta-lactamases in a tertiary-care medical center. J Clin Microbiol 1997; 35:2061-2067.
5. Karas JA, Pillay DG, Muckart D, Sturm AW. Treatment failure due to extended spectrum beta-lactamases. J Antimicrob Chemother 1996; 37:203-204.
6. Jorgensen JH, Turnidge JD, Washington JA. Antibacteria susceptibility tests: dilution and disk diffusion methods. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. 7th ed. Washington, DC: American Society of Microbiology; 1999.
7. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206-2012.